HOME >> MEDICINE >> NEWS
CellCept associated with reduced incidence of cancer, compared to AZA, following heart transplant

San Francisco, April 23, 2004 - A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCept (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens. Presented at the annual meeting of the International Society for Heart and Lung Transplantation (ISHLT), the study found a 27% lower risk of cancer in CellCept-treated patients. Patients studied were part of the ISHLT Transplant Registry. "Though not derived from randomized controlled trials, these data indicate that the choice of maintenance immunosuppressive regimen may be a modifiable risk factor for the development of malignancy in heart transplant recipients," said James O'Neill, M.D., Fellow in Heart Failure and Cardiac Transplantation, Cleveland Clinic.

Previous research had shown that organ transplant recipients receiving immunosuppressive therapy are three to four times more likely to develop tumors than the general population and have an even greater risk of developing certain rare cancers.

Extensive Examination of Registry Validates CellCept Treatment
The study, Mycophenolate Mofetil and the Risk of Developing Malignancy Following Orthotopic Heart Transplantation (OHT), examined competing risk factors to determine which are associated with malignancy following OHT, and was based on 3,895 patients in the ISHLT Transplant Registry. The study examined survival without malignancy in patients taking standard immunosuppressive regimens (defined as cyclosporine or tacrolimus and azathioprine or CellCept), who underwent OHT between January 1, 1995, and December 31, 1997.

Of these patients, 703 (18%) developed malignancy during the follow-up period through June 30, 2002. The breakdown of malignancy was as follows: skin (47%), post-transplant lymphoproliferative disease (10%),
'"/>

Contact: Julip Cantre
Julio.Cantre@ketchum.com
917-204-0599
Ketchum
23-Apr-2004


Page: 1 2 3

Related medicine news :

1. New data supports CellCepts position as a world leader in solid organ transplantation
2. CellCept(R) registry data demonstrated superior long-term organ transplant outcomes
3. CellCepts cardioprotective profile reinforced
4. Data shows life of kidney transplant lengthened by CellCept
5. Organizational traits associated with quality patient care are essential to home care nursing
6. Depression may explain higher risk of heart attack associated with antidepressants
7. Current daily smoking may be associated with increased risk for suicidal thoughts and attempts
8. Inpatient smoking cessation counseling is associated with early differences in mortality
9. Hypothyroidism associated with reduced breast cancer risk
10. COX-2 inhibitors associated with blood pressure elevation
11. Mothers depression associated with increased risk of childs antisocial behavior

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... ... to build intelligent, connected applications, was named the best Sales Team of 2016 ... winner announcement was made today by the Software & Information Industry Association (SIIA), ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers of ... a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes participating ... honor to be designated a Cigna Infertility Center of Excellence," said Fertility Centers ...
(Date:11/30/2016)... ... November 30, 2016 , ... Standard Process, Inc. ... annual ranking and recognition of the largest closely held companies headquartered in Wisconsin. ... 2008-2016. In addition, Standard Process was awarded the Talent Award for providing outstanding ...
(Date:11/30/2016)... MA (PRWEB) , ... November 30, 2016 , ... ... for treating injured workers have been a focus of public policymakers and system ... Compensation Research Institute (WCRI) released its Medical Price Index for Workers’ Compensation, ...
(Date:11/30/2016)... ... November 30, 2016 , ... The Valley’s leading orthopedic practice, ... of new North Phoenix and Chandler locations. , The new North Phoenix location ... 9327 North 3rd St, Suite 300 in Phoenix. The practice’s new Chandler location ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... North America held the largest share in the ... aged population and demand for remote monitoring ECG devices. On ... region is expected to witness the highest growth rate during ... Company (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... Netherlands ) and Mindray Medical International Limited ( ...
(Date:12/2/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... , , The global ultrasound ... is expected to grow at a CAGR of 5.5% during 2016-2022. Based ... during the forecast period, a CAGR of 8.8% in the global market. ...
(Date:12/2/2016)... FRANCISCO , Dec. 2, 2016  PipelineRx, a ... telepharmacy, will be offering demonstrations of its SaaS-based ... Society of Health-System Pharmacists 2016 Midyear Clinical Meeting ... Vegas . With nearly 300 hospital clients ... services and technology designed to dramatically improve pharmacy ...
Breaking Medicine Technology:
Cached News: